ChEMBL ligand: CHEMBL570812
Fatty acid amide hydrolase/Anandamide amidohydrolase in Human [ChEMBL: CHEMBL2243] [GtoPdb: 1400] [UniProtKB: O00519] Fatty acid amide hydrolase/Anandamide amidohydrolase in Rat [ChEMBL: CHEMBL3229] [GtoPdb: 1400] [UniProtKB: P97612] There should be some charts here, you may need to enable JavaScript!
monoacylglycerol lipase/Monoglyceride lipase in Human [ChEMBL: CHEMBL4191] [GtoPdb: 1399] [UniProtKB: Q99685] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
Fatty acid amide hydrolase/Anandamide amidohydrolase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2243] [GtoPdb: 1400] [UniProtKB: O00519]
ChEMBL	Inhibition of human recombinant FAAH-maltose binding protein	B	7.11	pIC50	77.62	nM	IC50	J Med Chem (2009) 52: 7310-7314 [PMID:19883085]
ChEMBL	Inhibition of FAAH (unknown origin)	B	7.12	pIC50	76	nM	IC50	Eur J Med Chem (2013) 63: 64-75 [PMID:23455058]
GtoPdb	-	-	7.85	pIC50	14	nM	IC50	J Enzyme Inhib Med Chem (2016) 31: 137-46 [PMID:25669350]
ChEMBL	Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate after 30 mins by fluorescence assay	B	7.85	pIC50	14	nM	IC50	Eur J Med Chem (2015) 97: 289-305 [PMID:26002335]
ChEMBL	Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate preincubated with protein for 0 min followed by substrate addition by fluorescence assay	B	7.89	pIC50	13	nM	IC50	Eur J Med Chem (2015) 97: 289-305 [PMID:26002335]
ChEMBL	Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate preincubated with protein for 30 mins followed by substrate addition by fluorescence assay	B	8.46	pIC50	3.5	nM	IC50	Eur J Med Chem (2015) 97: 289-305 [PMID:26002335]
ChEMBL	Inhibition of human recombinant FAAH using AMC arachidonoyl amide as substrate preincubated with protein for 60 mins followed by substrate addition by fluorescence assay	B	8.72	pIC50	1.9	nM	IC50	Eur J Med Chem (2015) 97: 289-305 [PMID:26002335]
Fatty acid amide hydrolase/Anandamide amidohydrolase in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3229] [GtoPdb: 1400] [UniProtKB: P97612]
ChEMBL	Inhibition of FAAH in Sprague-Dawley rat brain microsomes assessed as N-(2-hydroxyethyl)-4-pyren-1-ylbutanamide conversion to 4-pyren-1-ylbutanoic acid preincubated for 10 mins measured after 45 mins by HPLC analysis	B	5.89	pIC50	1300	nM	IC50	Eur J Med Chem (2013) 63: 64-75 [PMID:23455058]
ChEMBL	Inhibition of rat FAAH	B	7.07	pIC50	86	nM	IC50	J Med Chem (2017) 60: 4-46 [PMID:27766867]
ChEMBL	Inhibition of rat FAAH	B	7.07	pIC50	86	nM	IC50	J Med Chem (2020) 63: 5783-5796 [PMID:32429662]
monoacylglycerol lipase/Monoglyceride lipase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4191] [GtoPdb: 1399] [UniProtKB: Q99685]
ChEMBL	Inhibition of human recombinant MAGL-mediated 1,3-dihydroxypropan-1-yl 4-pyren-1-ylbutanoate conversion to 4-pyren-1-ylbutanoic acid preincubated for 15 mins measured after 45 mins by HPLC analysis	B	6.32	pIC50	480	nM	IC50	Eur J Med Chem (2013) 63: 64-75 [PMID:23455058]
ChEMBL	Inhibition of recombinant human MAGL using 1,3-dihydroxypropan-2-yl 4-pyren-1-yl-butanoate as substrate after 45 mins by fluorescence-based reversed phase HPLC analysis	B	6.32	pIC50	480	nM	IC50	Bioorg Med Chem (2017) 25: 825-837 [PMID:27989417]
ChEMBL	Inhibition of human recombinant MAGL using 1,3-dihydroxypropan-2-yl 4-pyren-1-ylbutanoate as substrate measured after 45 mins by reverse-phase HPLC-based fluorescence assay	B	6.32	pIC50	480	nM	IC50	J Med Chem (2020) 63: 13159-13186 [PMID:33089691]
ChEMBL	Inhibition of human MAGL using 4-Nitrophenylacetate as substrate	B	6.37	pIC50	424	nM	IC50	Eur J Med Chem (2016) 121: 318-330 [PMID:27267002]
ChEMBL	Inhibition of MAGL (unknown origin) using 4-nitrophenylacetate as substrate	B	6.4	pIC50	400	nM	IC50	Eur J Med Chem (2013) 63: 64-75 [PMID:23455058]
ChEMBL	Inhibition of human recombinant MAGL using 4-nitrophenylacetate as substrate	B	6.84	pIC50	146	nM	IC50	Bioorg Med Chem (2014) 22: 3285-3291 [PMID:24853323]
GtoPdb	-	-	6.84	pIC50	144	nM	IC50	J Enzyme Inhib Med Chem (2016) 31: 137-46 [PMID:25669350]
ChEMBL	Inhibition of human recombinant MAGL using 4-nitrophenylacetate as substrate after 30 mins	B	6.84	pIC50	144	nM	IC50	Bioorg Med Chem (2014) 22: 3285-3291 [PMID:24853323]
ChEMBL	Inhibition of recombinant human C-terminal His-tagged MAGL expressed in Escherichia coli using 4-NPA as substrate measured after 30 mins	B	6.85	pIC50	140	nM	IC50	Eur J Med Chem (2018) 157: 817-836 [PMID:30144699]
ChEMBL	Inhibition of recombinant human MAGL using 4-NPA as substrate after 30 mins by colorimetric analysis	B	6.85	pIC50	140	nM	IC50	J Med Chem (2018) 61: 1340-1354 [PMID:29309142]
ChEMBL	Inhibition of human recombinant MAGL using 4-NPA substrate incubated for 30 mins	B	6.87	pIC50	134	nM	IC50	J Med Chem (2016) 59: 10299-10314 [PMID:27809504]
ChEMBL	Inhibition of human recombinant MAGL using 4-NPA as substrate after 30 mins	B	6.87	pIC50	134	nM	IC50	J Med Chem (2019) 62: 1932-1958 [PMID:30715876]
ChEMBL	Inhibition of human recombinant MAGL using 4-nitrophenylacetate as substrate incubated for 30 mins by microplate reader assay	B	6.89	pIC50	130	nM	IC50	Eur J Med Chem (2021) 209: 112857-112857 [PMID:33045662]
ChEMBL	Inhibition of recombinant human MAGL	B	7.04	pIC50	92	nM	IC50	J Med Chem (2017) 60: 4-46 [PMID:27766867]
ChEMBL	Inhibition of MAGL (unknown origin)	B	7.04	pIC50	92	nM	IC50	Eur J Med Chem (2013) 63: 64-75 [PMID:23455058]
ChEMBL	Inhibition of human recombinant MAGL	B	7.04	pIC50	92	nM	IC50	J Med Chem (2020) 63: 5783-5796 [PMID:32429662]
ChEMBL	Inhibition of human recombinant MAGL using 4-nitrophenylacetate as substrate preincubated for 30 mins followed by substrate addition	B	7.59	pIC50	26	nM	IC50	Bioorg Med Chem (2014) 22: 3285-3291 [PMID:24853323]
ChEMBL	Inhibition of human MGL activity using [3H]2-oleoylglycerol substrate by liquid scintillation counting	B	7.69	pIC50	20.42	nM	IC50	J Med Chem (2009) 52: 7310-7314 [PMID:19883085]
ChEMBL	Inhibition of MAGL (unknown origin)	B	7.7	pIC50	20	nM	IC50	Eur J Med Chem (2016) 121: 318-330 [PMID:27267002]
ChEMBL	Inhibition of human MAGL using 4-Nitrophenylacetate substrate incubated for 15 mins	B	7.7	pIC50	20	nM	IC50	Bioorg Med Chem Lett (2014) 24: 3986-3996 [PMID:25011912]
ChEMBL	Inhibition of MAGL (unknown origin)	B	7.7	pIC50	20	nM	IC50	Bioorg Med Chem Lett (2021) 41: 127986-127986 [PMID:33766770]
ChEMBL	Inhibition of human recombinant MAGL using 4-nitrophenylacetate as substrate preincubated for 60 mins followed by substrate addition	B	8.05	pIC50	9	nM	IC50	Bioorg Med Chem (2014) 22: 3285-3291 [PMID:24853323]

ChEMBL data shown on this page come from version 33:

Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]